<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem. Biol</journal-id>
<journal-title>Frontiers in Chemical Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem. Biol</abbrev-journal-title>
<issn pub-type="epub">2813-530X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1400642</article-id>
<article-id pub-id-type="doi">10.3389/fchbi.2024.1400642</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemical Biology</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Keto-enol tautomerism in the development of new drugs</article-title>
<alt-title alt-title-type="left-running-head">Araujo de Oliveira et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchbi.2024.1400642">10.3389/fchbi.2024.1400642</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Araujo de Oliveira</surname>
<given-names>Ana Paula</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wegermann</surname>
<given-names>Camila Anchau</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1160187/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ferreira</surname>
<given-names>Ana Maria Da Costa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/999393/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Departamento de Qu&#xed;mica Fundamental</institution>, <institution>Instituto de Qu&#xed;mica</institution>, <institution>Universidade de S&#xe3;o Paulo</institution>, <addr-line>S&#xe3;o Paulo</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Universidade do Estado do Rio de Janeiro</institution>, <addr-line>Rio de Janeiro</addr-line>, <country>Brazil</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2025678/overview">Michal Jan Gajda</ext-link>, Migamake Pte Ltd, Singapore</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2294598/overview">Hector Alfredo Calderon</ext-link>, National Polytechnic Institute (IPN), Mexico</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1590063/overview">Bogdan Fedeles</ext-link>, Massachusetts Institute of Technology, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2695997/overview">Devendra Dhaked</ext-link>, National Institute of Pharmaceutical Education and Research, Kolkata, India</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Ana Maria Da Costa Ferreira, <email>amdcferr@iq.usp.br</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>3</volume>
<elocation-id>1400642</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Araujo de Oliveira, Wegermann and Ferreira.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Araujo de Oliveira, Wegermann and Ferreira</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The presence of isomers is a huge challenge in the development of new medicinal or pharmaceutical agents because the main goal is to obtain the most active compound with high purity and yield. Tautomerism is a phenomenon quite common in biomolecules that also appears in many drugs, and strategies to control the corresponding desired species and related equilibrium conditions leading to efficient chemical speciation are frequently required. There are many reports in the literature about the presence of tautomers, although some articles do not properly emphasize their occurrence or their importance for the differences verified in biological activity. Herein, a discussion about tautomers observed in both metalated and non-metalated compounds and their importance in the biological properties of promising drugs is revisited. Mainly, keto-enol equilibria among imines, hydrazones, and oxindole derivatives are showcased, based on significant examples, and strategies to improve their speciation or to better elucidate their modes of action are suggested.</p>
</abstract>
<kwd-group>
<kwd>chemical speciation</kwd>
<kwd>tautomerism</kwd>
<kwd>keto-enol equilibria</kwd>
<kwd>medicinal agents</kwd>
<kwd>promising scaffolds</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Structure, Spectroscopy &#x26; Imaging</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Speciation of an element refers to its distribution among defined chemical species formed or present in a system, according to the IUPAC definition (<xref ref-type="bibr" rid="B27">Templeton et al., 2000</xref>). Elemental speciation is commonly described by considering isotopic composition, oxidation state, inorganic, organic, and organometallic structures, and complexes with macromolecules (<xref ref-type="bibr" rid="B28">Templeton and Fujishiro, 2017</xref>). In many areas, particularly in catalysis, synthesis, separation of intermediate products, and pharmacology, the precise characterization of formed chemical species is crucial to achieving the best results in developing more efficient catalysts or more effective medicinal agents.</p>
<p>Isomers always constitute an important challenge in the synthesis and isolation of desired products. Selective formation of one of the isomers is sometimes possible in high purity and yield by choosing adequate conditions to shift the equilibrium to the more efficient isomeric form when performing the reactions. This is mostly important when a selected biological target is uniquely bound by only one of the isomeric species, and a more effective interaction with inhibitors is crucial.</p>
<p>Tautomers occur in many simple molecules and biomolecules, differing from each other frequently by protonation of the molecules in solution and, therefore, in a dependent correlation with the pH (<xref ref-type="bibr" rid="B20">Martin, 2018</xref>). Nucleobases can present tautomers that differ in the position of protons, and such structural differences play crucial roles in their hydrogen bonding interactions, leading to altered base pairing and consequently to serious effects on biochemical processes where nucleic acids are involved. For instance, minor tautomers that are transiently formed during replication could generate undesirable mutations (<xref ref-type="bibr" rid="B10">Fedeles et al., 2022</xref>).</p>
<p>Tautomeric equilibria are also intensely dependent on the dielectric constant of the medium and the ability of solvents to form hydrogen bonds with each tautomer. More polar solvents typically favor the more polar tautomer. Different techniques, mainly nuclear magnetic resonance (NMR), infrared (IR), ultraviolet (UV), Raman, X-ray diffraction, and terahertz spectroscopies are useful and have been used to monitor tautomers (<xref ref-type="bibr" rid="B3">Bharatam et al., 2023</xref>). A comprehensive tautomer database included more than 2,800 tautomeric structures, mainly prototropic tautomerism (79%) but also ring-chain and valence tautomerism (<xref ref-type="bibr" rid="B8">Dhaked et al., 2020</xref>).</p>
<p>Diverse classes of compounds with biological activity display tautomerism, such as oximes, oxindoles, diketones, and hydrazones, and are potentially valuable as building blocks in medicinal chemistry. Some of them have entered clinical tests, and a few of these have been approved as therapeutics (<xref ref-type="bibr" rid="B3">Bharatam et al., 2023</xref>), such as piroxicam, chlorthalidone, favipiravir, and topotecan (<xref ref-type="bibr" rid="B23">Sanna et al., 2005</xref>), discussed in <xref ref-type="sec" rid="s2">Section 2</xref>. In keto-enol tautomerization, a carbonyl double bond (keto form) is interconverted to an alkene double bond (enol form), simultaneously with the shift of the alpha proton in the keto form to the hydroxyl group in the enol form. A few examples of keto-enol tautomers with some pharmacological or medicinal interests are shown in <xref ref-type="scheme" rid="sch1">Scheme 1</xref>. Frequently, more than two tautomers can be formed.</p>
<fig id="sch1" position="float">
<label>SCHEME 1</label>
<caption>
<p>Keto-enol tautomers occurring in molecules with some pharmacological or medicinal interest: <bold>(A)</bold> <italic>Chlorthalidone</italic>, a drug to treat heart failure and renal impairment (<xref ref-type="bibr" rid="B26">Temperini et al., 2009</xref>); <bold>(B)</bold> <italic>curcumin</italic> (<xref ref-type="bibr" rid="B19">Manolova et al., 2014</xref>); <bold>(C)</bold> <italic>glibenclamide</italic>, an antidiabetic agent (<xref ref-type="bibr" rid="B35">Wolnica et al., 2019</xref>); <bold>(D)</bold> <italic>favipiravir</italic>, an anti-influenza drug (<xref ref-type="bibr" rid="B7">Deneva et al., 2023</xref>), and <bold>(E)</bold> <italic>topotecan</italic>, the most commonly used agent for the treatment of ovarian carcinoma (<xref ref-type="bibr" rid="B23">Sanna et al., 2005</xref>). <bold>(F)</bold> Possible amino-imino and keto-enol tautomers of nucleobase cytosine.</p>
</caption>
<graphic xlink:href="FCHBI_fchbi-2024-1400642_wc_sch1.tif"/>
</fig>
<p>In solution, tautomerism involves dynamic equilibria between two or more structurally different molecular forms in which a proton transfer (prototropy) usually occurs. Therefore, tautomers coexist as a mixture of possible compounds in concentrations proportional to their relative stability in a particular solvent. They usually show different properties such as water solubility, acid-base character, partition coefficient, or drug effectiveness. Tautomerization usually converts a hydrogen bond donor into an acceptor while simultaneously changing a hydrogen bond acceptor into a donor (<xref ref-type="bibr" rid="B20">Martin, 2018</xref>).</p>
<p>&#x3b2;-diketones constitute an early typical example of ligands capable of exhibiting keto-enol tautomerism, and because enolates can be easily formed, they give rise to metal complexes with several divalent metal ions (as Mn, Fe, Co, Ni, Zn, Cd, and Mg) acting as efficient Lewis acid catalysts, in addition to showing interesting structural features, and spectroscopic and magnetic properties (<xref ref-type="bibr" rid="B13">Graddon, 1969</xref>). These complexes commonly form octahedral, tetragonal, square planar, or tetrahedral structures, depending on the metal ion and on the steric effects caused by bulky ligands. With Lewis base molecules as water or amines, &#x3b2;-diketones can also form square-pyramidal adducts. In anhydrous conditions, they can even form polymeric species where the ligand act as a bridge between metal centers through their oxygen atoms (<xref ref-type="bibr" rid="B15">Hansen, 2021</xref>).</p>
<p>Recently, a novel strategy was developed to probe the G-protein coupled receptor domain rotation by introducing a tri-fluorinated group in a diketone compound and exploring the <sup>19</sup>F NMR signal variability and high sensitivity to changes in its surrounding environment based on keto-enol equilibrium (<xref ref-type="bibr" rid="B31">Wang H. et al., 2021</xref>). In this case, three tautomers are possible (enol-RCOCHCOHCF<sub>3</sub>, enol-RCOHCHCOCF<sub>3</sub>, and diketo-RCOCH<sub>2</sub>COCF<sub>3</sub>), and the fluorinated derivative marker showed very distinct, not overlapping signals that were extremely sensitive to the microenvironment of the protein. Therefore, the opposite movements of different receptor domains could be monitored spectroscopically relative to the protein hydrophobic core as a result of an existent tautomeric equilibrium.</p>
<p>In many reported cases, the desirable most active tautomer was not appropriately detected and characterized, or its importance in explaining the mode of action is not evident. Sometimes, the biological target is found to interact with a less stable tautomer instead of the expected predominant one in solution.</p>
<p>Herein, a selected series of molecules with potential application as pharmacological or medicinal agents that show possible tautomeric species are discussed, with the aim of better understanding their influence in interactions with main biological targets in their mechanisms of action and pointing out some strategies to achieve the most effective or desired tautomer. These molecules display tautomerism even when metalated, although the coordination to metal ions frequently leads to the preferential stabilization of one of the tautomers.</p>
</sec>
<sec id="s2">
<title>2 Selected examples of the influence of tautomers in the reactivity of drugs</title>
<p>Over the last decades, the influence of tautomerism in drug discovery has elicited a huge interest, discussed in terms of thermodynamic and kinetic aspects, where different methodologies, mainly NMR but also infrared, were used to monitor tautomeric equilibria in solution (<xref ref-type="bibr" rid="B5">Claramunt et al., 2006</xref>; <xref ref-type="bibr" rid="B1">Alkorta et al., 2020</xref>), and often including support by extensive simulation studies (<xref ref-type="bibr" rid="B17">Katritzky et al., 2010</xref>; <xref ref-type="bibr" rid="B11">G&#xf6;ller, 2022</xref>). An extensive open-source database reporting measured and estimated tautomer ratios, mainly in water, is available (<xref ref-type="bibr" rid="B30">Wahl and Sander, 2020</xref>). A hybrid quantum-classical workflow was proposed to predict the relative stability of tautomers to identify the dominant species (<xref ref-type="bibr" rid="B24">Shee et al., 2023</xref>). Recently, complex data mining on tautomeric polymorphism in crystal structure databases was reported (<xref ref-type="bibr" rid="B36">Woods-Ryan et al., 2023</xref>), extending its interest beyond aqueous solutions or solvents to the solid state.</p>
<p>There are some interesting examples of drugs in which the presence of tautomers is crucial for their medicinal properties. Sulfonamides such as the therapeutic <italic>chlorthalidone</italic> (shown in <xref ref-type="scheme" rid="sch1">Scheme 1A</xref>), a widely prescribed drug in the United States, used to treat high blood pressure, swelling, diabetes insipidus, and renal impairment, show an irregular pattern of inhibition toward carbonic anhydrase, an enzyme that presents several isoforms (<xref ref-type="bibr" rid="B26">Temperini et al., 2009</xref>). X-ray crystal structure analysis revealed the effect of tautomerization on the selectivity of inhibition, with the enol form being the most effective through the formation of strong hydrogen bonds with residues Thr200 and Asn67, besides three water molecules at W142, W146, and W161 (2.54&#x2013;3.16&#xa0;&#xc5;) in the active site of the enzyme.</p>
<p>Curcumin (shown in <xref ref-type="scheme" rid="sch1">Scheme 1B</xref>), found in an Asian <italic>Curcuma longa</italic> plant, shows diverse therapeutic properties, being investigated as an anti-inflammatory, antiviral, antibacterial, antifungal, and anticancer agent. It also shows tautomeric equilibria (see <xref ref-type="scheme" rid="sch1">Scheme 1</xref>) involving three tautomers (<xref ref-type="bibr" rid="B19">Manolova et al., 2014</xref>). The effectiveness of the pharmacological activity of curcumin is limited by its poor solubility, fast metabolism, fast systemic elimination, and, therefore, low bioavailability. Therefore, different techniques and analytical methods for improving curcumin formulations in diverse matrices have been developed, trying to improve its biological activity (<xref ref-type="bibr" rid="B29">Uro&#x161;evi&#x107; et al., 2022</xref>). A strong predominance of the KE tautomer in solid state and in organic solvents was reported in many studies. However, when inserted in a calix[4]arene host system, results indicated that the binding of the KK tautomer is more favorable (by 1.7&#xa0;kcal/mol in water) than the binding of the preferred tautomeric KE form (<xref ref-type="bibr" rid="B2">Angelova and Antonov, 2017</xref>).</p>
<p>
<italic>Topotecan</italic> (Hycamtin; GlaxoSmithKline), an antitumor agent from the class of camptothecins, is commonly used against ovarian carcinoma and was also approved for the treatment of small-cell lung cancer, which is a lethal malignancy (shown in <xref ref-type="scheme" rid="sch1">Scheme 1E</xref>). It shows three different types of enol and keto tautomers and has topoisomerase I, an essential enzyme in DNA replication, transcription, and recombination, as the main target (<xref ref-type="bibr" rid="B23">Sanna et al., 2005</xref>).</p>
<p>
<italic>Piroxicam</italic>, a non-steroidal anti-inflammatory drug described as very effective against various inflammatory conditions, can exist in seven different tautomeric forms, and it seems that the enol-amide form is the most stable, present in ethanol or DMSO solution as a monomer-dimer equilibrium. However, in addition to its therapeutic uses, there are some reports of undesirable effects correlated to its structural characteristics (<xref ref-type="bibr" rid="B16">Ivanova et al., 2015</xref>). Only its neutral species was suggested to be biologically active, and by the addition of water, the equilibrium shifted to the zwitterionic tautomer. Therefore, it is crucial to understand the conversion between tautomers to define the desired drug action and its better mode of delivery.</p>
<p>
<italic>Favipiravir</italic>, an anti-influenza drug (see <xref ref-type="scheme" rid="sch1">Scheme 1D</xref>) that was also tested against the SARS-CoV-2 virus, had its tautomers studied by molecular spectroscopy (UV/Vis absorption, fluorescence, and NMR), as well as by DFT quantum chemical calculations (<xref ref-type="bibr" rid="B7">Deneva et al., 2023</xref>). The enol form is the most stable in many organic solvents, although the equilibrium is shifted in the presence of water, and a keto form appears to be favored due to drug&#x2013;solvent interactions. With the addition of Mg<sup>2&#x2b;</sup> or Ca<sup>2&#x2b;</sup> ions, complexes [ML<sub>2</sub>] are formed at a 2:1 ligand:metal ratio, both in the enol or keto tautomeric state, with coordination by an amide -C&#x3d;O(NH<sub>2</sub>) and a keto group, or by an amide -C&#x3d;O(NH<sub>2</sub>) and an enol group. It seems that a simultaneous tautomeric transition and complexation occur, preceded by a change from the most stable enol form to the keto form or by a deprotonation followed by complexation in the case of the enol tautomer, as shown in <xref ref-type="scheme" rid="sch1">Scheme 1D</xref> (<xref ref-type="bibr" rid="B7">Deneva et al., 2023</xref>).</p>
<p>In the development of new promising drugs, a wide range of different ligands and corresponding metal complexes have been investigated regarding the occurrence of tautomerism.</p>
<p>Oximes exhibit diverse biological and pharmacological applications, including antibacterial, antifungal, anti-inflammatory, antioxidant, and anticancer activities, and usually are found in the form of interconvertible <italic>E</italic> and <italic>Z</italic> stereoisomers, showing different physical and pharmacological properties (<xref ref-type="bibr" rid="B9">Dhuguru et al., 2022</xref>). Studies usually indicated that <italic>Z-</italic>isomers are more stable and predominant than <italic>E</italic>-isomers. Oximes can also show three main tautomeric forms: oximes, nitrones, and nitroso compounds. Particularly, some derivatives of indirubin, an indole-based oxime (<xref ref-type="bibr" rid="B32">Wang X. et al., 2021</xref>), have been broadly investigated for their anticancer activity, probably due to their strong affinity for cyclin-dependent kinases (CDKs), proteins with an essential role in controlling cell cycle and proliferation (<xref ref-type="bibr" rid="B18">Knockaert et al., 2002</xref>). Different pharmacological inhibitors of CDKs that contain an oxindole moiety in their structure show possible tautomers and are being tested for diverse diseases (cancer, neurodegenerative, cardiovascular, parasitic, or viral infections). Indirubin itself has 26 possible <italic>E/Z</italic> isomers and tautomers, some of which are more stable than others (<xref ref-type="bibr" rid="B1">Alkorta et al., 2020</xref>). A recent publication reports a very rapid keto-enol tautomerization (&#x3c;1&#xa0;ps) when an oxime group is introduced in an indirubin derivative, promoting an excited-state proton transfer process and additionally improving the photostability of the compound compared to the precursor (<xref ref-type="bibr" rid="B21">Nobre et al., 2024</xref>).</p>
<p>Hydrazones constitute another versatile class of compounds that show tautomers and are used in a wide range of biological applications as antibacterials, antiprotozoals, antifungals, antituberculars, anticonvulsants, anti-inflammatories, cytotoxic agents, antimalarials, antivirals, and vasodilator agents (<xref ref-type="bibr" rid="B25">Sztanke et al., 2013</xref>). Aroylhydrazones exhibiting keto-enol tautomerism formed a series of deprotonated enolate species with marked antitumor activity. This activity was significantly improved when coordinated with copper(II) ions and having a pyridine as a co-ligand (<xref ref-type="bibr" rid="B12">Gou et al., 2017</xref>). In methanol solution of free ligands, the keto form is more stable, with tautomerization energy being approximately a few kcal/mol, according to quantum chemical calculations. In contrast, the inverse conversion of enol to keto forms was predicted to require more than 60&#xa0;kcal/mol (<xref ref-type="bibr" rid="B12">Gou et al., 2017</xref>). Similar results were observed with tridentate hydrazone-zinc(II) and manganese(II) complexes; [ML<sub>2</sub>] in distorted octahedral species was isolated in enolate forms where a strong intermolecular H-bonding interaction between two ligand units occurs (<xref ref-type="bibr" rid="B22">Ray et al., 2008</xref>).</p>
</sec>
<sec id="s3">
<title>3 Metal complexes showing keto-enol tautomerism</title>
<p>In our studies of oxindole derivatives, tautomers of corresponding imines and hydrazones (shown in <xref ref-type="scheme" rid="sch2">Scheme 2</xref>) were found to have a crucial role in their biological activities. Oxindole groups show intrinsic keto-enol tautomerism, and this characteristic remains in its derivatives, such as imines or hydrazones, as well as in corresponding metalated species (<xref ref-type="bibr" rid="B38">da Silveira et al., 2008</xref>; <xref ref-type="bibr" rid="B39">da Silveira et al., 2009</xref>). Particularly when coordinated with essential metal ions such as copper or zinc, the influence of their structural features on the reactivity exhibited was critical. This influence took the form of improving its biological activities, mainly by improving its ability to make hydrogen bonds with targeted biomolecules.</p>
<fig id="sch2" position="float">
<label>SCHEME 2</label>
<caption>
<p>Some oxindolimine <bold>(A)</bold> and hydrazone <bold>(B)</bold> ligands and corresponding metal complexes <bold>(C)</bold> showing keto-enol tautomerism. Both copper(II) complexes with ligand <italic>isaepy</italic> were isolated, monitored, and characterized by ESI-MS measurements, showing both signals due to tautomeric equilibrium (M:L 1:1, enol form, and M:L 1:2, keto form). Other metal complexes were isolated in one of the tautomeric forms.</p>
</caption>
<graphic xlink:href="FCHBI_fchbi-2024-1400642_wc_sch2.tif"/>
</fig>
<p>In aqueous solution, the keto forms of free oxindolimine ligands are favored, isolated preferentially at pH 5 (<xref ref-type="bibr" rid="B40">Cerchiaro et al., 2005</xref>). The proportion of the enol form increases at pH &#x2265; 8. In contrast, the coordination of such ligands to metal ions stabilizes mostly the corresponding enol forms. Particularly, complexes with enol tautomers of tridentate ligands, as ligand <italic>isaepy</italic> (see <xref ref-type="scheme" rid="sch2">Scheme 2</xref>), seem to be the most active due to their more planar structure and the presence of a labile water molecule in the coordination sphere. At physiological pH, those tautomers show stronger donor&#x2013;acceptor interactions with biomolecules such as DNA or proteins through hydrogen bond formation.</p>
</sec>
<sec id="s4">
<title>4 Strategies to favor the most active tautomeric species</title>
<p>A recent study on the tautomerism observed in <italic>glibenclamide</italic> (see <xref ref-type="scheme" rid="sch1">Scheme 1C</xref>), an important pharmaceutical for diabetes mellitus (type 2), indicated that the amide-to-imide ratio was different if the active pharmaceutical was prepared in the glass state (bulk system) or in the form of spin-coated homogeneously distributed thin films with various thickness (49&#x2013;220&#xa0;nm) (<xref ref-type="bibr" rid="B35">Wolnica et al., 2019</xref>). Kinetic curves obtained from infrared data for the bulk system follow the sigmoidal shape, characteristic of the autocatalytic reaction, while results obtained for the confined samples provide exponential character, indicating first-order transformation. It seems that the autocatalytic nature of tautomerization in bulk samples arises from the initial formation of the amide form that further catalyzes the amide-imide transformation.</p>
<p>In our studies on supported oxindolimine-copper(II) complexes, we verified that the tautomeric equilibria can be shifted not only in solution by pH variation but also by interactions of the metal complexes with different inorganic matrices.</p>
<p>In solution, oxindolimine-metal complexes have their properties as antitumor agents modulated by both the nature of the metal ion and by the structural features of the coordinated ligand in a synergistic way. When inserted or supported in inorganic matrices, such as beidellite clay or functionalized silica (MCM- and MCM-atzac) materials, the tautomeric equilibria suffered some remarkable shifts, as monitored by IR and Raman spectroscopies (<xref ref-type="bibr" rid="B14">Vieira et al., 2019</xref>). The hybrid materials MCM-[Zn(isapn)] and MCM-atzac-[Zn(isapn)] show high discrepancy when compared to the free [Zn(isapn)]<sup>&#x2b;</sup> spectral profile due to H-bond interactions with the matrix, probably indicating a preferential stabilization of one of the tautomers, probably the keto-enol form. In contrast, a remarkable similarity of results with MCM-[Cu(isapn)] and MCM-atzac-[Cu(isapn)] compared to those of free copper complex attested to the absence of such interaction factors. When supported in beidellite, the asymmetric keto-enol form of ligand <italic>isapn</italic> is favored (<xref ref-type="bibr" rid="B6">Couto et al., 2023</xref>) for both copper(II) and zinc(II) compounds.</p>
<p>Studies of the influence of analogous hydrazones derived from oxindoles in the aggregation inhibition of &#x3b2;&#x2212;amyloid peptides, enhanced in the presence of metal ions such as copper, zinc, or iron, indicated the possibility of six isomers, detected by NMR spectroscopy among the <italic>E-</italic> and <italic>Z-</italic>forms, and corresponding keto-enol tautomers (<xref ref-type="bibr" rid="B33">Wegermann et al., 2022</xref>). DFT simulations supported the experimental results, attesting that the most stable isomers in solution are the keto isomers in corresponding <italic>Z-</italic>forms. However, these studies also attested that there is a proton transfer from the hydrazone ligand to the amyloid peptide (A&#x3b2;<sub>1-16</sub>), interfering in the tautomeric equilibrium, favoring the enol form (<xref ref-type="bibr" rid="B34">Wegermann et al., 2023</xref>). A pioneering work on curcumin binding to amyloid aggregates reports the predominant presence of the enol form and that the enolization is crucial for this interaction, making it a powerful tool for the detection of and therapy for Alzheimer&#x2019;s disease (<xref ref-type="bibr" rid="B37">Yanagisawa et al., 2010</xref>).</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>5 Conclusion</title>
<p>Tautomeric equilibria continue to elicit great interest in both chemical (structural and spectroscopic features) and biological studies (interactions and activity). Different classes of ligands (imines, hydrazones, polyphenols, oximes, and oxindoles) exhibit tautomers that show different reactivity toward biomolecules and, thus, significantly influence their properties and applications. More in-depth studies could provide better conditions for developing new and more efficient compounds regarding each of the possible tautomeric forms in order to optimize their syntheses and explore their potential medicinal uses more accurately.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Author contributions</title>
<p>AF: conceptualization, formal analysis, funding acquisition, investigation, supervision, writing&#x2013;original draft, and writing&#x2013;review and editing. AA: formal analysis, investigation, writing&#x2013;original draft, and writing&#x2013;review and editing. CW: formal analysis, investigation, writing&#x2013;original draft, and writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors are thankful to the Sao Paulo State Research Foundation (FAPESP, project CEPID Redoxoma, grant 2013/07937-8) for financial support. They are also grateful to Portal CAPES for providing access to the literature.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author AF declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkorta</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Elguero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dardonville</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reviriego</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Santa Mar&#xed;a</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Claramunt</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A theoretical and spectroscopic (NMR and IR) study of indirubin in solution and in the solid state</article-title>. <source>J. Phys. Org. Chem.</source> <volume>33</volume>, <fpage>4043</fpage>. <pub-id pub-id-type="doi">10.1002/poc.4043</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angelova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Antonov</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Molecular insight into inclusion complex formation of curcumin and calix[4]arene</article-title>. <source>Chem. Sel.</source> <volume>2</volume>, <fpage>9658</fpage>&#x2013;<lpage>9662</lpage>. <pub-id pub-id-type="doi">10.1002/slct.201701865</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bharatam</surname>
<given-names>P. V.</given-names>
</name>
<name>
<surname>Valanju</surname>
<given-names>O. R.</given-names>
</name>
<name>
<surname>Wani</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Dhaked</surname>
<given-names>D. K.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Importance of tautomerism in drugs</article-title>. <source>Drug Discov. Today</source> <volume>28</volume>, <fpage>103494</fpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2023.103494</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerchiaro</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aquilano</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Filomeni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rotilio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ciriolo</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Da Costa Ferreira</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Isatin-Schiff base copper(II) complexes and their influence on cellular viability</article-title>. <source>J. Inorg. Biochem.</source> <volume>99</volume>, <fpage>1433</fpage>&#x2013;<lpage>1440</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2005.03.013</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claramunt</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>L&#xf3;pez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Santa Mar&#xed;a</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Elguero</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The use of NMR spectroscopy to study tautomerism</article-title>. <source>ChemInform</source> <volume>38</volume>, <fpage>169</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1002/chin.200711279</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couto</surname>
<given-names>R. A. A.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>E. G.</given-names>
</name>
<name>
<surname>Brendl&#xe9;</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Limousy</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Constantino</surname>
<given-names>V. R. L.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Synthetic beidellite clay as nanocarrier for delivery of antitumor oxindolimine-metal complexes</article-title>. <source>J. Inorg. Biochem.</source> <volume>240</volume>, <fpage>112099</fpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2022.112099</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deneva</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Slavova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumanova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vassilev</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nedeltcheva-Antonova</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Antonov</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Favipiravir&#x2014;tautomeric and complexation properties in solution</article-title>. <source>Pharmaceuticals</source> <volume>16</volume>, <fpage>45</fpage>. <pub-id pub-id-type="doi">10.3390/ph16010045</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>da Silveira</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Graziani</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ciriolo</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Da Costa Ferreira</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Double-strand DNA cleavage induced by Oxindole-Schiff base copper(II) complexes with potential antitumor activity</article-title>. <source>J. Inorg. Biochem.</source> <volume>102</volume>, <fpage>1090</fpage>&#x2013;<lpage>1103</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2007.12.033</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>da Silveira</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Caramori</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Gon&#xE7;alves</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Petrilli</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Da Costa Ferreira</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Oxindole-Schiff base copper(II) complexes interactions with human serum albumin: spectroscopic, oxidative damage, and computational studies</article-title>. <source>J. Inorg. Biochem.</source> <volume>103</volume>, <fpage>1331</fpage>&#x2013;<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2009.05.015</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhaked</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Guasch</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Nicklaus</surname>
<given-names>M. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Tautomer database: a comprehensive resource for tautomerism analyses</article-title>. <source>J. Chem. Inf. Model.</source> <volume>60</volume>, <fpage>1090</fpage>&#x2013;<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.9b01156</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhuguru</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zviagin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Skouta</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>FDA-approved oximes and their significance in medicinal chemistry</article-title>. <source>Pharmaceuticals</source> <volume>15</volume>, <fpage>66</fpage>. <pub-id pub-id-type="doi">10.3390/ph15010066</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fedeles</surname>
<given-names>B. I.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Structural insights into tautomeric dynamics in nucleic acids and in antiviral nucleoside analogs</article-title>. <source>Front. Mol. Biosci.</source> <volume>8</volume>, <fpage>823253</fpage>. <pub-id pub-id-type="doi">10.3389/fmolb.2021.823253</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>G&#xf6;ller</surname>
<given-names>A. H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Reliable gas-phase tautomer equilibria of drug like molecule scaffolds and the issue of continuum solvation</article-title>. <source>J. Comput. Aided Mol. Des.</source> <volume>36</volume>, <fpage>805</fpage>&#x2013;<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-022-00480-3</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Structure and biological properties of mixed-ligand Cu(II) Schiff base complexes as potential anticancer agents</article-title>. <source>Eur. J. Med. Chem.</source> <volume>134</volume>, <fpage>207</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2017.04.026</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graddon</surname>
<given-names>D. P.</given-names>
</name>
</person-group> (<year>1969</year>). <article-title>Divalent transition metal &#x3b2;-keto-enolate complexes as lewis acids</article-title>. <source>Coord. Chem. Rev.</source> <volume>4</volume>, <fpage>1</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/S0010-8545(00)80090-9</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guimar&#xe3;es Vieira</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Miguel</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Rodrigues da Silva</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Boni Fazzi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>de Couto</surname>
<given-names>R. A. A.</given-names>
</name>
<name>
<surname>Marin</surname>
<given-names>J. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Functionalized nanoparticles as adjuvant to increase the cytotoxicity of metallodrugs toward tumor cells</article-title>. <source>New J. Chem.</source> <volume>43</volume>, <fpage>386</fpage>&#x2013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1039/c8nj04654a</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>P. E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Structural studies of &#x3b2;-diketones and their implications on biological effects</article-title>. <source>Pharmaceuticals</source> <volume>14</volume>, <fpage>1189</fpage>. <pub-id pub-id-type="doi">10.3390/ph14111189</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivanova</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Deneva</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nedeltcheva</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kamounah</surname>
<given-names>F. S.</given-names>
</name>
<name>
<surname>Gergov</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>P. E.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Tautomeric transformations of piroxicam in solution: a combined experimental and theoretical study</article-title>. <source>RSC Adv.</source> <volume>5</volume>, <fpage>31852</fpage>&#x2013;<lpage>31860</lpage>. <pub-id pub-id-type="doi">10.1039/c5ra03653d</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katritzky</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>El-Gendy</surname>
<given-names>B. E. D. M.</given-names>
</name>
<name>
<surname>Draghici</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Tautomerism in drug discovery</article-title>. <source>J. Comput. Aided Mol. Des.</source> <volume>24</volume>, <fpage>475</fpage>&#x2013;<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-010-9359-z</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knockaert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Greengard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Meijer</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Pharmacological inhibitors of cyclin-dependent kinases</article-title>. <source>TRENDS Pharmacol. Sci.</source> <volume>23</volume>, <fpage>417</fpage>&#x2013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-6147(02)02071-0</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manolova</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Deneva</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Antonov</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Drakalska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Momekova</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lambov</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The effect of the water on the curcumin tautomerism: a quantitative approach</article-title>. <source>Spectrochimica Acta Part A Mol. Biomol. Spectrosc.</source> <volume>132</volume>, <fpage>815</fpage>&#x2013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1016/j.saa.2014.05.096</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>Y. C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Experimental and pK prediction aspects of tautomerism of drug-like molecules</article-title>. <source>Drug Discov. Today Technol.</source> <volume>27</volume>, <fpage>59</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2018.06.006</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nobre</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Delgado-Pinar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cunha</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>S&#xe9;rgio Seixas de Melo</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The role of the oxime group in the excited state deactivation processes of indirubin</article-title>. <source>Phys. Chem. Chem. Phys.</source> <volume>26</volume>, <fpage>7416</fpage>&#x2013;<lpage>7423</lpage>. <pub-id pub-id-type="doi">10.1039/d3cp05260e</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ray</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Rosair</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Garland</surname>
<given-names>M. T.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Two Zn(II) and one Mn(II) complexes using two different hydrazone ligands: spectroscopic studies and structural aspects</article-title>. <source>Struct. Chem.</source> <volume>19</volume>, <fpage>209</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1007/s11224-007-9274-7</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanna</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chillemi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Grandi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Castelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Desideri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barone</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>New hints on the pH-driven tautomeric equilibria of the topotecan anticancer drug in aqueous solutions from an integrated spectroscopic and quantum-mechanical approach</article-title>. <source>J. Am. Chem. Soc.</source> <volume>127</volume>, <fpage>15429</fpage>&#x2013;<lpage>15436</lpage>. <pub-id pub-id-type="doi">10.1021/ja052637u</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>T.-L.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Quantum simulation of preferred tautomeric state prediction</article-title>. <source>NPJ Quantum Inf.</source> <volume>9</volume>, <fpage>102</fpage>. <pub-id pub-id-type="doi">10.1038/s41534-023-00767-9</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sztanke</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Maziarka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Osinka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sztanke</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>An insight into synthetic Schiff bases revealing antiproliferative activities <italic>in vitro</italic>
</article-title>. <source>Bioorg. Med. Chem.</source> <volume>21</volume>, <fpage>3648</fpage>&#x2013;<lpage>3666</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2013.04.037</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Temperini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cecchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Scozzafava</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Supuran</surname>
<given-names>C. T.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the Keto&#x2212;Enol tautomerism make the difference</article-title>. <source>J. Med. Chem.</source> <volume>52</volume>, <fpage>322</fpage>&#x2013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1021/jm801386n</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Templeton</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Ariese</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cornelis</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Danielsson</surname>
<given-names>L. G.</given-names>
</name>
<name>
<surname>Muntau</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Van Leeuwen</surname>
<given-names>H. P.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Guidelines for terms related to chemical speciation and fractionation of elements. Definitions, structural aspects, and methodological approaches (IUPAC recommendations 2000)</article-title>. <source>Pure Appl. Chem.</source> <volume>72</volume>, <fpage>1453</fpage>&#x2013;<lpage>1470</lpage>. <pub-id pub-id-type="doi">10.1351/pac200072081453</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Templeton</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Fujishiro</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Terminology of elemental speciation &#x2013; an IUPAC perspective</article-title>. <source>Coord. Chem. Rev.</source> <volume>352</volume>, <fpage>424</fpage>&#x2013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2017.02.002</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uro&#x161;evi&#x107;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nikoli&#x107;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gaji&#x107;</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nikoli&#x107;</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dini&#x107;</surname>
<given-names>A. ; V.</given-names>
</name>
<name>
<surname>Miljkovi&#x107;</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Curcumin: biological activities and modern pharmaceutical forms</article-title>. <source>Antibiot. (Basel)</source> <volume>11</volume>, <fpage>135</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics11020135</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wahl</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Tautobase: an open tautomer database</article-title>. <source>J. Chem. Inf. Model.</source> <volume>60</volume>, <fpage>1085</fpage>&#x2013;<lpage>1089</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00035</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>Anticancer potential of indirubins in medicinal chemistry: biological activity, structural modification, and structure-activity relationship</article-title>. <source>Eur. J. Med. Chem.</source> <volume>223</volume>, <fpage>113652</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113652</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Al-Abdul-Wahid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Madsen</surname>
<given-names>J. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Trifluorinated keto-enol tautomeric switch in probing domain rotation of a G protein-coupled receptor</article-title>. <source>Bioconjugate Chem.</source> <volume>32</volume>, <fpage>99</fpage>&#x2013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.0c00670</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wegermann</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Monzani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Casella</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Bruzeguini</surname>
<given-names>C. E. T.</given-names>
</name>
<name>
<surname>Vilcachagua</surname>
<given-names>J. D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Unveiling geometrical isomers and tautomers of isatin-hydrazones by NMR spectroscopy</article-title>. <source>J. Mol. Struct.</source> <volume>1250</volume>, <fpage>131633</fpage>. <pub-id pub-id-type="doi">10.1016/j.molstruc.2021.131633</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wegermann</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Pirota</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Monzani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Casella</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>L. A. S.</given-names>
</name>
<name>
<surname>Novato</surname>
<given-names>W. T. G.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Interaction studies of oxindole-derivatives with &#x3b2;-amyloid peptides inhibiting its aggregation induced by metal ions</article-title>. <source>J. Inorg. Biochem.</source> <volume>245</volume>, <fpage>112227</fpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2023.112227</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolnica</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Szklarz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dulski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wojtyniak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tarnacka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaminska</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Studying tautomerism in an important pharmaceutical glibenclamide confined in the thin nanometric layers</article-title>. <source>Colloids Surfaces B Biointerfaces</source> <volume>182</volume>, <fpage>110319</fpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2019.06.049</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woods-Ryan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Cruz-Cabeza</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>A to Z of polymorphs related by proton transfer</article-title>. <source>Cryst. Eng. Comm.</source> <volume>25</volume>, <fpage>2845</fpage>&#x2013;<lpage>2858</lpage>. <pub-id pub-id-type="doi">10.1039/D3CE00216K</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yanagisawa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shirai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Amatsubo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hirao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Urushitani</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Relationship between the tautomeric structures of curcumin derivatives and their A&#x3b2;-binding activities in the context of therapies for Alzheimer&#x2019;s disease</article-title>. <source>Biomaterials</source> <volume>31</volume>, <fpage>4179</fpage>&#x2013;<lpage>4185</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.01.142</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>